ORIC anticipates the following upcoming milestones: Rinzimetostat in mCRPC: 1Q 2026: Combination dose optimization data with AR inhibitor; 1H 2026: Initiate first global Phase 3 registrational trial in mCRPC. 2H 2026: Program update Enozertinib in NSCLC: 2H 2026: 1L EGFR exon 20 monotherapy data and combination data with SC amivantamab; 2H 2026: 1L EGFR PACC monotherapy data
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORIC:
- Piper Sandler Puts its Weight Behind 2 ‘Strong Buy’ Cancer Stocks
- ORIC Pharmaceuticals: Dense Near‑Term Clinical Catalysts and Encouraging Efficacy Data Underpin Reiterated Buy Rating
- Oric Pharmaceuticals provides operational highlights for 2025
- 3 Best Biotech Stocks to Buy Today, 1/7/2026, According to Top Analysts
- Oric Pharmaceuticals initiated with an Overweight at Piper Sandler